{"id":"W2888094806","doi":"10.1016/j.ejca.2018.07.007","title":"A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Halozyme; Novocure; Celgene; Pfizer; Oncolytics Biotech; Eli Lilly and Company","keywords":"Gemcitabine; Capecitabine; Medicine; Tolerability; Cisplatin; Internal medicine; Oncology; Paclitaxel; Clinical endpoint; Chemotherapy; Phases of clinical research; Adenocarcinoma; Deoxycytidine; Surgery; Gastroenterology; Clinical trial; Cancer; Adverse effect","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002243045,0.0002532025,0.001541223,0.0003409074,0.00006923224,0.00001817378,0.0001845605,0.00005326463,0.0009123792],"category_scores_gemma":[0.001494719,0.0001407252,0.00008193592,0.0004924127,0.0005197282,0.0001627482,0.00005277154,0.0004561118,0.000004511695],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001692391,"about_ca_system_score_gemma":0.001716052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009188937,"about_ca_topic_score_gemma":0.0004854855,"domain_scores_codex":[0.9968892,0.0005738129,0.001210465,0.000268225,0.0006341312,0.000424137],"domain_scores_gemma":[0.9973905,0.0004566679,0.000676254,0.0002943523,0.0008479718,0.0003342352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9488729,0.0005254829,0.02754095,0.0002336889,0.0003972403,0.001515444,0.001387135,0.00001298637,0.003714066,0.00000507833,0.0004758106,0.01531925],"study_design_scores_gemma":[0.9121537,0.05382727,0.02401902,0.002264684,0.0007630234,0.0007770393,0.0007975553,0.002290871,0.000674048,0.000009227857,0.002198887,0.0002246499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990089,0.003184676,0.001164547,0.0007625654,0.0001198382,0.001344056,0.00001154188,0.000009604477,0.003314161],"genre_scores_gemma":[0.9852169,0.001339526,0.007391184,0.0001634523,0.0007634533,0.00002884478,0.00000282845,0.00005933522,0.005034501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05330179,"threshold_uncertainty_score":0.9989913,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03735224206187664,"score_gpt":0.3747354699927424,"score_spread":0.3373832279308657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}